Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
Open accessThe DOI matches its Crossref record.
Abstract
Since the 1950s, replacement of immunoglobulin G using human immunoglobulin has been the standard treatment for primary immunodeficiency diseases with defects in antibody production. These patients suffer from recurrent and severe infections, which cause lung damage and shorten their life span. Immunoglobulins given intravenously (IVIG) every 3-4 weeks are effective in preventing serious bacterial infections and improving the quality of life for treated patients. Administration of immunoglobulin subcutaneously (SCIG) is equally effective in preventing infections and has a lower incidence of serious adverse effects compared to IVIG. The tolerability and acceptability of SCIG has been demonstrated in numerous studies showing improvements in quality of life and a preference for subcutaneous immunoglobulin therapy in patients with antibody deficiencies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
Ulrichts, P., Guglietta, A., Dreier, T., van Bragt, T., Hanssens, V., Hofman, E., Vankerckhoven, B., Verheesen, P., Ongenae, N., Lykhopiy, V., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97911 · Cited by 427
Wasserman, R. L. (2017) · Immunotherapy · doi:10.2217/imt-2017-0092 · Cited by 77
Subcutaneous Immunoglobulin for Primary and Secondary Immunodeficiencies: an Evidence-Based Review
Lingman-Framme, J., & Fasth, A. (2013) · Drugs · doi:10.1007/s40265-013-0094-3 · Cited by 71
Metadata
- Authors
- Kobrynski, L.
- Venue
- Biologics: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2012-08
- Volume
- 6
- Pages
- 277
- ISSN
- 1177-5475 (ISSN-L)
- OpenAlex
- W1973841362
- Cited by
- 81
- References
- 0
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. https://app.cochat.ai/papers/10.2147/btt.s25188
- The paper
- Kobrynski, L. (2012). Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics: Targets and Therapy. https://doi.org/10.2147/btt.s25188
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.